Psyomics opens up to seed funding

Psyomics, a UK-based developer of digital tools for mental health diagnosis and treatment spun out of University of Cambridge, has obtained an undisclosed seed sum from unnamed investors, BusinessWeekly has reported.
Founded in 2015, Psyomics builds digital and biomarker-powered tools for the diagnosis and prevention of mental health conditions in occupational, clinical and primary care settings. The aim is to provide greater credibility to mental health evaluations than is possible from conventional modes of diagnosis.
Psyomics has already created a technology differentiating between bipolar disorder and depression, as well as a digital health platform called Tresilio that helps individuals manage their mental health through an app-like interface. The capital will enable it to add to its headcount and increase engagement with clinicians such as general practitioners (GPs).
Psyomics will use the capital to expand its headcount and increase its engagement with clinicians including general practitioners (GPs) in primary care.
The spinout was co-founded by Sabine Bahn, chair of neurotechnology at University of Cambridge and director of its Cambridge Centre for Neuropsychiatric Research.
Psyomics previously obtained an undisclosed sum of funding in 2017 from two vehicles operated by fund manager Parkwalk Advisors – Parkwalk Opportunities Fund and University of Cambridge Enterprise Fund V – the latter of which acts as a co-investment fund backing technologies from the university.
Parkwalk Advisors had already backed Psyomics through University of Cambridge Enterprise Fund IV in 2016, investing an undisclosed sum sized at $530,000 in a quarterly bulletin published by trade journal SpinoutsUK.
Commercialisation firm IP Group now owns Parkwalk Advisors, having acquired the business in late 2017.